• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾细胞癌中的 miRNA 谱分析提示局限性透明细胞肾细胞癌中存在一组促血管生成肿瘤。

miRNA profiling in renal carcinoma suggest the existence of a group of pro-angionenic tumors in localized clear cell renal carcinoma.

机构信息

Biomedica Molecular Medicine SL, Madrid, Spain.

Urology Service, Hospital Universitario 12 de Octubre, Madrid, Spain.

出版信息

PLoS One. 2020 Feb 28;15(2):e0229075. doi: 10.1371/journal.pone.0229075. eCollection 2020.

DOI:10.1371/journal.pone.0229075
PMID:32109249
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7048408/
Abstract

Renal cell carcinoma comprises a variety of entities, the most common being the clear-cell, papillary and chromophobe subtypes. These subtypes are related to different clinical evolution; however, most therapies have been developed for clear-cell carcinoma and there is not a specific treatment based on different subtypes. In this study, one hundred and sixty-four paraffin samples from primary nephrectomies for localized tumors were analyzed. MiRNAs were isolated and measured by microRNA arrays. Significance Analysis of Microarrays and Consensus Cluster algorithm were used to characterize different renal subtypes. The analyses showed that chromophobe renal tumors are a homogeneous group characterized by an overexpression of miR 1229, miR 10a, miR 182, miR 1208, miR 222, miR 221, miR 891b, miR 629-5p and miR 221-5p. On the other hand, clear cell renal carcinomas presented two different groups inside this histological subtype, with differences in miRNAs that regulate focal adhesion, transcription, apoptosis and angiogenesis processes. Specifically, one of the defined groups had an overexpression of proangiogenic microRNAs miR185, miR126 and miR130a. In conclusion, differences in miRNA expression profiles between histological renal subtypes were established. In addition, clear cell renal carcinomas had different expression of proangiogenic miRNAs. With the emergence of antiangiogenic drugs, these differences could be used as therapeutic targets in the future or as a selection method for tailoring personalized treatments.

摘要

肾细胞癌包括多种实体瘤,最常见的是透明细胞癌、乳头状癌和嫌色细胞癌亚型。这些亚型与不同的临床演变有关;然而,大多数治疗方法都是针对透明细胞癌开发的,并没有针对不同亚型的特定治疗方法。在这项研究中,分析了 164 例局部肿瘤行肾切除术的石蜡样本。通过 microRNA 芯片分离并测量 microRNAs。采用差异表达分析和共识聚类算法来描述不同的肾亚型。分析表明,嫌色细胞肾肿瘤是一个同质群体,其特征是 miR 1229、miR 10a、miR 182、miR 1208、miR 222、miR 221、miR 891b、miR 629-5p 和 miR 221-5p 的过表达。另一方面,透明细胞肾细胞癌在这个组织学亚型内呈现出两个不同的群体,其 miRNA 调节焦点粘附、转录、凋亡和血管生成过程存在差异。具体来说,定义的一个组中过表达了促血管生成的 microRNAs miR185、miR126 和 miR130a。总之,建立了组织学肾亚型之间 microRNA 表达谱的差异。此外,透明细胞肾细胞癌有不同的促血管生成 microRNAs 表达。随着抗血管生成药物的出现,这些差异将来可以作为治疗靶点,或作为制定个体化治疗方案的选择方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99bd/7048408/0683af32ffc8/pone.0229075.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99bd/7048408/1b2b49d2c374/pone.0229075.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99bd/7048408/a21fd7e3a922/pone.0229075.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99bd/7048408/09c3d72061dc/pone.0229075.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99bd/7048408/764dfc2531ca/pone.0229075.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99bd/7048408/18bb84cf1771/pone.0229075.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99bd/7048408/9d4813bd6177/pone.0229075.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99bd/7048408/0683af32ffc8/pone.0229075.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99bd/7048408/1b2b49d2c374/pone.0229075.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99bd/7048408/a21fd7e3a922/pone.0229075.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99bd/7048408/09c3d72061dc/pone.0229075.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99bd/7048408/764dfc2531ca/pone.0229075.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99bd/7048408/18bb84cf1771/pone.0229075.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99bd/7048408/9d4813bd6177/pone.0229075.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99bd/7048408/0683af32ffc8/pone.0229075.g007.jpg

相似文献

1
miRNA profiling in renal carcinoma suggest the existence of a group of pro-angionenic tumors in localized clear cell renal carcinoma.肾细胞癌中的 miRNA 谱分析提示局限性透明细胞肾细胞癌中存在一组促血管生成肿瘤。
PLoS One. 2020 Feb 28;15(2):e0229075. doi: 10.1371/journal.pone.0229075. eCollection 2020.
2
MicroRNA expression profiling of Xp11 renal cell carcinoma.Xp11肾细胞癌的微小RNA表达谱分析
Hum Pathol. 2017 Sep;67:18-29. doi: 10.1016/j.humpath.2017.03.011. Epub 2017 Apr 12.
3
MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.微小RNA-194是透明细胞肾细胞癌预后良好的标志物。
Cancer Med. 2016 Apr;5(4):656-64. doi: 10.1002/cam4.631. Epub 2016 Feb 10.
4
Cooperative Effect of miR-141-3p and miR-145-5p in the Regulation of Targets in Clear Cell Renal Cell Carcinoma.miR-141-3p与miR-145-5p在透明细胞肾细胞癌靶标调控中的协同作用
PLoS One. 2016 Jun 23;11(6):e0157801. doi: 10.1371/journal.pone.0157801. eCollection 2016.
5
MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases.具有预后潜力的微小 RNA 可用于预测透明细胞肾细胞癌的转移:原发肿瘤与远处转移的比较。
Ann Surg Oncol. 2014 Mar;21(3):1046-54. doi: 10.1245/s10434-013-3361-3. Epub 2013 Nov 18.
6
Molecular Characterization of Renal Cell Carcinoma: A Potential Three-MicroRNA Prognostic Signature.肾细胞癌的分子特征:一种潜在的三 miRNA 预后标志物。
Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):464-472. doi: 10.1158/1055-9965.EPI-17-0700. Epub 2018 Feb 12.
7
The miR-200 family as prognostic markers in clear cell renal cell carcinoma.作为透明细胞肾细胞癌预后标志物的miR-200家族
Urol Oncol. 2019 Dec;37(12):955-963. doi: 10.1016/j.urolonc.2019.08.008. Epub 2019 Oct 19.
8
Oncogenic MicroRNAs Characterization in Clear Cell Renal Cell Carcinoma.透明细胞肾细胞癌中致癌性微小RNA的特征分析
Int J Mol Sci. 2015 Dec 8;16(12):29219-25. doi: 10.3390/ijms161226160.
9
MicroRNA profiling of human kidney cancer subtypes.人类肾癌亚型的微小RNA分析
Int J Oncol. 2009 Jul;35(1):109-14. doi: 10.3892/ijo_00000318.
10
Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c.肾细胞癌全基因组微小RNA表达谱分析:miR-141和miR-200c显著下调
J Pathol. 2008 Dec;216(4):418-27. doi: 10.1002/path.2437.

引用本文的文献

1
Overexpression of Long Non-Coding RNA MIR22HG Represses Proliferation and Enhances Apoptosis via miR-629-5p/TET3 Axis in Osteosarcoma Cells.长链非编码 RNA MIR22HG 的过表达通过 miR-629-5p/TET3 轴抑制骨肉瘤细胞增殖并增强细胞凋亡。
J Microbiol Biotechnol. 2021 Oct 28;31(10):1331-1342. doi: 10.4014/jmb.2106.06028.
2
Methylation and expression levels of microRNA-23b/-24-1/-27b, microRNA-30c-1/-30e, microRNA-301a and let-7g are dysregulated in clear cell renal cell carcinoma.miR-23b/miR-24-1/miR-27b、miR-30c-1/miR-30e、miR-301a 和 let-7g 的甲基化和表达水平在肾透明细胞癌中失调。
Mol Biol Rep. 2021 Jul;48(7):5561-5569. doi: 10.1007/s11033-021-06573-w. Epub 2021 Jul 24.
3

本文引用的文献

1
The role and mechanisms of action of microRNAs in cancer drug resistance.微小 RNA 在癌症药物耐药性中的作用和作用机制。
Clin Epigenetics. 2019 Feb 11;11(1):25. doi: 10.1186/s13148-018-0587-8.
2
What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial.对于中高危肾细胞癌切除术后,需要怎样的生存获益才能使辅助性索拉非尼治疗变得值得?SORCE试验中临床研究者的偏好。
Kidney Cancer. 2018 Aug 1;2(2):123-131. doi: 10.3233/KCA-180038.
3
Cancer statistics, 2019.
The Ambivalent Role of miRNAs in Carcinogenesis: Involvement in Renal Cell Carcinoma and Their Clinical Applications.
微小RNA在肿瘤发生中的矛盾作用:与肾细胞癌的关系及其临床应用
Pharmaceuticals (Basel). 2021 Apr 2;14(4):322. doi: 10.3390/ph14040322.
癌症统计数据,2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
4
Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.辅助舒尼替尼治疗高危肾细胞癌患者的安全性、治疗管理和患者报告结局:S-TRAC 试验。
Ann Oncol. 2018 Oct 1;29(10):2098-2104. doi: 10.1093/annonc/mdy329.
5
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial.阿昔替尼对比安慰剂作为肾细胞癌的辅助治疗:来自 III 期、随机对照 ATLAS 试验的结果。
Ann Oncol. 2018 Dec 1;29(12):2371-2378. doi: 10.1093/annonc/mdy454.
6
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.癌症基因组图谱对肾细胞癌的全面分子特征分析。
Cell Rep. 2018 Apr 3;23(1):313-326.e5. doi: 10.1016/j.celrep.2018.03.075.
7
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.帕唑帕尼辅助治疗对比安慰剂用于局限性或局部进展性肾细胞癌患者肾切除术后的随机III期试验
J Clin Oncol. 2017 Dec 10;35(35):3916-3923. doi: 10.1200/JCO.2017.73.5324. Epub 2017 Sep 13.
8
Adjuvant sunitinib in renal cell carcinoma: from evidence to recommendation.
Ann Oncol. 2017 Apr 1;28(4):682-684. doi: 10.1093/annonc/mdx014.
9
MicroRNA Stability in FFPE Tissue Samples: Dependence on GC Content.福尔马林固定石蜡包埋(FFPE)组织样本中的微小RNA稳定性:对GC含量的依赖性。
PLoS One. 2016 Sep 20;11(9):e0163125. doi: 10.1371/journal.pone.0163125. eCollection 2016.
10
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.《2016 年世界卫生组织泌尿系统及男性生殖器官肿瘤分类—第 A 部分:肾脏、阴茎和睾丸肿瘤》。
Eur Urol. 2016 Jul;70(1):93-105. doi: 10.1016/j.eururo.2016.02.029. Epub 2016 Feb 28.